Kinase Inhibitor

Bruton's Tyrosine Kinase Inhibitors

Lymphoma, Mantle-Cell

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>BRUKINSA (zanubrutinib) is a kinase inhibitor. The empirical formula of zanubrutinib is C27H29N5O3and the chemical name is (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide. Zanubrutinib is a white to off-white powder, with a pH of 7.8 in saturated solution. The aqueous solubility of zanubrutinib is pH dependent, from very slightly soluble to practically insoluble.The molecular weight of zanubrutinib is 471.55 Daltons.Zanubrutinib has the following structure:<img alt="Chemical Structure" src="brukinsa-01.jpg"/>Each BRUKINSA capsule for oral administration contains 80 mg zanubrutinib and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The capsule shell contains edible black ink, gelatin, and titanium dioxide.</section>

BRUKINSA

zanubrutinib

zanubrutinib 80 MG Oral Capsule

Brukinsa

zanubrutinib 80 MG Oral Capsule [Brukinsa]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Pharmacy List 

Submit MSL Request 

Reimbursement Information

Formulary Information

How To Order Brukinsa 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity

Brukinsa Enrollment Form 

Enroll in Patient Savings Program 

Enroll in Bridge Program 

Patient Assistance Program 

Comprehensive Support Program 

Comprehensive Support Program - Phone Number For Patients 

About Brukinsa: Waldenström’s Macroglobulinemia (WM)

Taking Brukinsa: Waldenström’s Macroglobulinemia (WM)

About Brukinsa: Mantle Cell Lymphoma (MCL)

Taking Brukinsa: Mantle Cell Lymphoma (MCL)

About Brukinsa: Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Taking Brukinsa: Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Instructions For Use: Waldenström’s Macroglobulinemia (WM)

Instructions For Use: Mantle Cell Lymphoma (MCL)

Instructions For Use: Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Other HCP Resources

Patient Resources 

Patient Management Guide - AEs

Patient Brochure 

Patient Brochure - Spanish 

Patient Brochure - Chinese 

myBeiGene Patient Support Program Brochure 

myBeiGene Patient Support Program Brochure - Spanish

myBeiGene Patient Support Program Brochure - Chinese 

Sample Request